

December 9, 2019



# Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

*- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET*

Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will host a symposium on the endocannabinoid system ("ECS") and the therapeutic potential of targeting the ECS. The symposium will be webcasted live (details below) on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET.

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will host the event, and Barbara White, M.D., Chief Medical Officer and Head of Research of Corbus will moderate the panel session. The panel session will feature presentations from the following experts:

- *The ECS and resolution of inflammation;*  
Charles N. Serhan, Ph.D., DSc, First Endowed Distinguished Scientist, Brigham and Women's Hospital, currently serving as Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women's Hospital. Simon Gelman Professor of Anesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School, Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine
- *The ECS and skin inflammation;*  
Adam Friedman, M.D., FAAD, Interim Chair, Department of Dermatology and Professor of Dermatology, George Washington University School of Medicine and Health Sciences
- *Potential applicability of targeting the ECS to treat autoimmune diseases: Lenabasum in systemic sclerosis;*  
Jessica Gordon, M.D., Associate Professor of Medicine, Weill Cornell Medical College, Associate Attending in the Department of Rheumatology at the Hospital for Special Surgery in New York

## Webcast Details

Interested participants may dial into the event using (877) 407-3978 (domestic) or (412) 902-0039 (international), or can access the live [video webcast](#) and accompanying slide presentation on the [Events](#) page of the [Investors](#) section of the Corbus website, [www.corbuspharma.com](http://www.corbuspharma.com). The webcast replay will be archived for 90 days following the event.

## **About Corbus**

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others. Corbus expects data from a CRB-4001 Phase 1 safety study in 2020.

For more information, please visit [www.CorbusPharma.com](http://www.CorbusPharma.com) and connect with the Company on [Twitter](#), [LinkedIn](#), and [Facebook](#).

## **Forward-Looking Statements**

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

## **Corbus Pharmaceuticals Contacts:**

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications  
Phone: +1 (617) 415-7745  
Email: [ir@corbuspharma.com](mailto:ir@corbuspharma.com)

Lindsey Smith, Associate Director, Investor Relations and Corporate Communications  
Phone: +1 (617) 415-7749  
Email: [mediainfo@corbuspharma.com](mailto:mediainfo@corbuspharma.com)

Jenene Thomas  
Jenene Thomas Communications, LLC  
Phone: +1 (833) 475-8247  
Email: [crbp@jtcir.com](mailto:crbp@jtcir.com)



Source: Corbus Pharmaceuticals Holdings, Inc.